logo
A frequent flyer needed a kidney transplant to live. This Delta worker gave him one

A frequent flyer needed a kidney transplant to live. This Delta worker gave him one

CNN9 hours ago
Bruce Gamble has been flying out of Birmingham, Alabama, since the late 1980s for his job as a consultant for car dealerships. Along the way, he got to know Delta Air Lines employees at Birmingham-Shuttlesworth International Airport pretty well, making a point of greeting the customer service agents during his almost weekly travels.
Jill Hickey, a part-time Delta agent who's been with the airline for four years, got used to seeing Gamble stop by the customer service counter to get a water after his flights. Little did either of them know those encounters would save his life.
Hickey, 57, said she believes she crossed paths with Gamble for a reason.
'I knew Bruce had been having some health concerns, but I didn't know the extent, how serious it was, and what it was that he needed,' Hickey said.
In November 2022, Gamble, now 74, discovered he needed a kidney transplant. Gamble has been a Type 2 diabetic since 2002, and an internist noticed his kidney function was declining. He was told his blood type had a three-to-five-year waiting list for a kidney from a deceased donor. By then, he would be 75 to 78 years old, ruling out surgery. He was left with no option but to be 'an advocate' for himself, he said.
'It really started when somebody would say, 'How are you doing today, Bruce?' and I said, 'I'm doing fine, except I just need to find a kidney donor,'' he told CNN.
That revelation 'opened the whole conversation up' about what donating an organ entailed, he said, including compatibility testing and making sure the donor is healthy. He started talking to people about his search for a kidney during his trips to the airport and just about anywhere else he went.
The wait Gamble faced is average at most centers for a kidney transplant from a deceased donor, but in some parts of the country, it can be even longer than five years.
Waiting times depend on several things, including the length of time a patient has been on dialysis or on the transplant waitlist; blood type; where the patient lives; and their antibody levels, according to the National Kidney Foundation.
But a kidney transplant from a living donor can be faster.
One evening, some Delta employees were talking about ways to help Gamble, whom they had all met at one time or another through his trips in Birmingham. Hickey overheard her coworkers' conversation.
She and a coworker decided together that they would get tested.
When she brought the idea to her family, her husband and kids questioned her a lot. She's a mother of two daughters, both in their late 20s, and one of her daughters was in tears out of fear of what could happen in surgery. But her family ultimately understood why she wanted to help.
Hickey works as an elementary school teacher for gifted children during the day. Throughout her career in education, Hickey has met students who needed organ donations. Recalling those moments in her life, she said, made her want to help someone who might be in that same situation.
If healthy and able, Hickey was going to donate.
'I was stunned, beside myself,' Gamble said when he learned of Hickey's intention. He told his wife of 51 years that a donor had emerged from all the time he'd spent spreading the word.
Kidneys transplanted from a living donor are more likely to start working right away and may last longer than those from a deceased donor. Kidneys from living donors last an average of about 15 to 20 years, according to the National Kidney Foundation, compared with 7 to 10 years for those from deceased donors.
A person can live a full life with one kidney but must protect the remaining organs by staying as healthy as possible, the foundation says.
Over two years, Gamble had 10 other people volunteer to be tested, but all were disqualified for varying reasons — then came Hickey, the 11th person to be tested.
Not everyone who wants to donate is able to give, but the test found that Hickey and Gamble were fully compatible.
'When Jill called me and said she was an exact match, I can't tell you – I was just speechless at that point,' Gamble said. 'But here we are. God blessed me with Jill at this point in my life. She's extending my life, and I've told her that many times.'
Hickey's decision felt especially fateful after she was gifted a daily devotion book from a friend of Bruce's. She opened the page to the date of the surgery, and it read, 'Let Me lead you step by step through this day. If your primary focus is on Me, you can walk along perilous paths without being afraid.'
'It really solidified my faith that everything is going to be all right, that I'm here for a purpose,' Hickey said. 'Our paths crossed at the right time for a reason.'
Gamble's desperate search for a donor isn't unusual. There are not nearly enough organs to fill kidney transplant needs.
About 90,000 people are on the kidney transplant waitlist, according to data from the federal Health Resources and Services Administration cited by the National Kidney Foundation. In 2023, about 27,000 people received a kidney transplant — and roughly 6,300 of those were from living donors.
Gamble and Hickey underwent surgeries in December 2024 in Birmingham. During the procedure, doctors discovered issues with the blood vessels around Hickey's kidney that could have caused more health problems. The result was a longer surgery, but one that still went smoothly.
Months after the surgery, Hickey, Gamble and their spouses went on a trip to California. Gamble has collected animation art for over 35 years. On their trip, Hickey bought artwork of Marvin the Martian, which Gamble hopes will 'get her hooked' on the hobby.
Hickey said that Gamble's love for animation art sparked creative ideas that will apply to her teaching job. The two couples enjoyed spending time together and they say it won't be their last vacation as a group.
Donation doesn't change life expectancy for donors. In fact, some studies, according to the National Kidney Foundation, have shown living donors live longer than the average person because only the healthiest people are accepted for kidney donation.
In some ways, life has gone back to the way things were before. Hickey is teaching gifted children full-time during the school year, and she works for Delta as a customer service agent in the evenings. Gamble travels on occasion. He's 'semi-retired' but continues to do some training at car dealerships.
In one important way, however, things are forever changed.
'We were strangers at first, but we're more like family now,' Hickey said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025
60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

Yahoo

time34 minutes ago

  • Yahoo

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

Data from three independent clinical studies demonstrate utility of tafenoquine to treat acute canine babesiosis WASHINGTON, July 14, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ('60 Degrees' or the 'Company'), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that the Company will conduct a gap analysis of its existing data prior to submitting a Minor Use Minor Species (MUMS) designation request to the United States Food and Drug Administration (FDA) for tafenoquine for the treatment of acute canine babesiosis. The submission will be based on results of three clinical efficacy studies that evaluated ARAKODA® (tafenoquine) for canine babesiosis, and existing canine safety data and chemistry manufacturing and controls (CMC) data for tafenoquine generated through the clinical development of ARAKODA for malaria. The clinical efficacy studies involved experimental Babesia infections and dogs diagnosed with naturally acquired Babesia infection in veterinary clinics. One of the studies was company-sponsored and conducted at North Carolina State University. Collectively, the studies showed that tafenoquine, administered as ARAKODA tablets, was well tolerated and appeared to facilitate recovery from acute infection. Every year in the United States, several hundred to several thousand cases of canine babesiosis are seen. It is an emerging tick-borne illness carried by the same tick vector as Lyme Disease. No FDA-approved oral treatment for canine babesiosis exists, and currently available treatments carry significant toxicity risk or the propensity to generate drug resistance. 'Data from the canine babesiosis studies are impactful when viewed in the larger context of the ground-breaking human babesiosis research we are now sponsoring,' said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoff Dow. 'The positive findings of the canine babesiosis study are in line with our earlier findings that tafenoquine could be effective against babesiosis in humans.' About ARAKODA® (tafenoquine)Tafenoquine was discovered by Walter Reed Army Institute of Research. Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only malaria prevention drug. According to the Centers for Disease Control and Prevention, the long terminal half-life of tafenoquine, which is approximately 16 days, offers the advantage of less frequent dosing for the prophylaxis of malaria. ARAKODA® is not suitable for everyone, and patients and prescribers should review the Important Safety Information below. Individuals at risk of contracting malaria are prescribed ARAKODA® 2 x 100 mg tablets once per day for three days (the loading phase) prior to travel to an area of the world where malaria is endemic, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel. Tafenoquine has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the U.S. Food and Drug Administration for such an indication. ARAKODA® (tafenoquine) Important Safety Information ARAKODA® is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. Contraindications ARAKODA® should not be administered to: Glucose-6-phosphate dehydrogenase ('G6PD') deficiency or unknown G6PD status; Breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if G6PD status is unknown; Patients with a history of psychotic disorders or current psychotic symptoms; or Known hypersensitivity reactions to tafenoquine, other 8-aminoquinolines, or any component of ARAKODA®. Warnings and Precautions Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA® due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis. G6PD Deficiency in Pregnancy or Lactation: ARAKODA® may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. ARAKODA® is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA® through breast milk. Check infant's G6PD status before breastfeeding begins. Methemoglobinemia: Asymptomatic elevations in blood methemoglobin have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia occur. Psychiatric Effects: Serious psychotic adverse reactions have been observed in patients with a history of psychosis or schizophrenia, at doses different from the approved dose. If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA® therapy and evaluation by a mental health professional as soon as possible. Hypersensitivity Reactions: Serious hypersensitivity reactions have been observed with administration of ARAKODA®. If hypersensitivity reactions occur, institute appropriate therapy. Delayed Adverse Reactions: Due to the long half-life of ARAKODA® (approximately 16 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and hypersensitivity reactions may be delayed in onset and/or duration. Adverse Reactions: The most common adverse reactions (incidence greater than or equal to 1 percent) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase (ALT), motion sickness, insomnia, depression, abnormal dreams, and anxiety. Drug Interactions Avoid co-administration with drugs that are substrates of organic cation transporter-2 or multidrug and toxin extrusion transporters. Use in Specific Populations Lactation: Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during treatment and for 3 months after the last dose of ARAKODA®. To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees Pharmaceuticals, Inc. at 1- 888-834-0225 or the FDA at 1-800-FDA-1088 or The full prescribing information of ARAKODA® is located here. About 60 Degrees Pharmaceuticals, Inc.60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. Cautionary Note Regarding Forward-Looking StatementsThis press release may contain 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission ('SEC'), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC's website at As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contacts:Sheila A. BurkeSheilaBurke-consultant@ 667-6330 Investor Contact:Patrick Gaynespatrickgaynes@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

New Jersey woman nearly dies after taking dangerous amount of popular supplement: ‘I was very, very, very scared'
New Jersey woman nearly dies after taking dangerous amount of popular supplement: ‘I was very, very, very scared'

Yahoo

timean hour ago

  • Yahoo

New Jersey woman nearly dies after taking dangerous amount of popular supplement: ‘I was very, very, very scared'

A New Jersey woman says she almost died after taking daily turmeric pills, a popular supplement found in grocery stores. Katie Mohan, a 57-year-old from Morristown, told she sustained liver damage after taking daily pills of turmeric, a yellow spice widely used for its antioxidant and anti-inflammatory properties. Mohan said her first symptoms included fatigue, nausea, stomach pain and yellowing eyes, which are a sign of jaundice. Mohan first saw her doctor in April, but the scans and tests ordered came back normal. Her symptoms continued to get worse until June, when Mohan read an NBC News story about a man with similar symptoms who found out he had a drug-induced liver injury after taking turmeric daily. 'I threw [the supplements] out, and I said to myself, 'I'm wondering if this is what's causing my symptoms,'' Mohan told Mohan bought the turmeric pills, which were manufactured by YouTheory, at Costco, reports. The product states the daily dose is three pills containing 2,250 milligrams, Mohan said, which is over the World Health Organization's recommendation of up to 3 milligrams per kilogram of body weight per day. A New Jersey woman says she damaged her liver by taking daily turmeric supplements (Getty Images) After reading the NBC News article, Mohan went to urgent care. From there, she was admitted to Morristown Medical Center, where doctors found that she had severe liver damage. She was treated with an antiviral IV drip, but her skin was still yellowing. Mohan recalled thinking: 'Am I going to need a liver transplant? Am I going to die?' 'I was very, very, very scared,' she added. That's when she was transferred to NYU Langone in New York. There, her doctor found 'evidence of acute hepatitis, impending liver failure and potential transplant evaluation.' 'She was really very sick,' Dr. Nikolaos Pyrsopoulos, told 'Her liver numbers were 60 to 70 times above the normal limit. And she was very yellow.' Mohan said Pyrsopoulos confirmed her fears that the turmeric caused her symptoms. Katie Mohan said she was worried she would need a liver transplant after taking too much turmeric (Getty Images) 'He's like, 'You essentially poisoned the liver with the turmeric,'' she said. 'It was the dose combined with the fact that it had that black pepper in it.' Pyrsopoulos told that his hospital sees three to four liver transplants per year related to turmeric poisoning. Mohan has since been discharged and says her liver enzyme levels are still elevated, but they're continuing to fall and her symptoms have completely disappeared. Mohan has since reported the supplements to the Food and Drug Administration. The Independent has contacted Costco and YouTheory for comment.

New York official again rebuffs Texas judgment against doctor over abortion pills
New York official again rebuffs Texas judgment against doctor over abortion pills

Yahoo

timean hour ago

  • Yahoo

New York official again rebuffs Texas judgment against doctor over abortion pills

By Daniel Wiessner (Reuters) -A county official in New York on Monday rejected for a second time efforts by Texas to enforce a $100,000 judgment against a New York doctor accused of violating Texas' ban on abortion by sending abortion pills to the state, further escalating an unprecedented interstate conflict. Acting Ulster County Clerk Taylor Bruck in a letter to the office of Republican Texas Attorney General Ken Paxton doubled down on his March finding that New York's so-called shield law precludes the enforcement of other states' abortion bans against New Yorkers. Paxton's office last week had asked Bruck to reconsider, arguing that he had a legal duty to enforce the judgment against New Paltz, New York-based doctor Margaret Carpenter. Bruck on Monday said Paxton's office had not presented any new information. "While I'm not entirely sure how things work in Texas, here in New York, a rejection means the matter is closed," wrote Bruck, who is running for county clerk as a Democrat. Paxton's office and the Abortion Coalition for Telemedicine, a group co-founded by Carpenter, did not immediately respond to requests for comment. New York Governor Kathy Hochul, a Democrat who championed the passage of the shield law earlier this year, praised Bruck for "defending the freedom generations of women fought to secure." "Our response to (Texas') baseless claim is clear: no way in hell. New York won't be bullied," Hochul said in a statement. Medication abortion accounts for more than half of U.S. abortions. It has drawn increasing attention since the U.S. Supreme Court's 2022 decision allowing states to ban abortion, which more than 20 states, including Texas, have done. A judge in Collin County, Texas, entered a default judgment against Carpenter in February after she failed to respond to the state's civil lawsuit alleging she illegally prescribed mifepristone and misoprostol, the two drugs used in medication abortion, to a Texas woman via telemedicine. Carpenter has also been indicted by a Louisiana grand jury for prescribing an abortion pill that was taken by a teenager there, in what appeared to be the first time a state criminally charged a doctor in another state for prescribing abortion drugs. Hochul in February rejected Louisiana's request to extradite Carpenter there.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store